Adimab vs Mabylon
Adimab vs Mabylon, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Adimab is on 53/100 and Mabylon on 35/100.
Where each one leads
Adimab
- our overall score: 53/100 against 35/100
- agent readiness: 40/100 against 30/100
- domain rating: 39/100 against 32/100
- funding raised: $105M against $35.8M
Mabylon
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Adimab | Mabylon |
|---|---|---|
| What it is | Adimab is a biotechnology company that discovers and develops therapeutic antibodies using its proprietary yeast-based platform. | Mabylon is a biotechnology company focused on developing innovative antibody-based therapies for infectious diseases and cancer. |
| Category | Biotech, Drug Discovery, Antibody Discovery, Therapeutic Antibodies | Biotech, MedTech, Drug Discovery, Antibody Therapeutics |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2007 | Not published |
| Headquarters | Lebanon, United States | Geneva, Switzerland |
| Status | Active | Active |
Size, funding and growth
| Measure | Adimab | Mabylon |
|---|---|---|
| Employees | 139 | Not published |
| Total funding | $105M | $35.8M |
| Latest round | Series B | Series A |
| LinkedIn followers | 8,423 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Adimab | Mabylon |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 53/100 | 35/100 |
| Traction | 60/100 | 38/100 |
| Search visibility | 20/100 | 2/100 |
| Quality | 68/100 | 45/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (40/100) | F (30/100) |
| Domain ratingLink authority, 0-100 | 39/100 | 32/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Adimab | Mabylon |
|---|---|---|
| Hosting | AWS | Self Managed |
| CMS | WordPress | Not detected |
| Frameworks | Jquery, Bootstrap | Jquery, Bootstrap |
| Analytics | Google Tag Manager, Linkedin Insight | Google Analytics 4 |
| Support stack | HubSpot | Not detected |
Adimab vs Mabylon: common questions
Which is better, Adimab or Mabylon?
On our 0-100 score Adimab rates higher (53/100 against 35/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.
How do Adimab and Mabylon compare on the numbers?
Adimab leads on our overall score (53/100 against 35/100), agent readiness (40/100 against 30/100), domain rating (39/100 against 32/100), funding raised ($105M against $35.8M).
Read the full Adimab review and pricing or the Mabylon review and pricing. You can also browse other Adimab alternatives we track.